▼ bearish
Impact
PhasePhase 1 (discontinued)
Time to marketNot applicable — program discontinued
GTx-101 bupivacaine topical spray Updated Sep 12
What to watch
GTx-101 has been formally discontinued and written off. Investors should ignore this asset entirely, Grace Therapeutics' stock is now a pure binary play on the GTx-104 NDA resubmission timeline and FDA outcome. Monitor the company's progress on manufacturing remediation and stability data milestones for GTx-104, not GTx-101.
Bull case
- The PK bridging study met all primary outcome measures, demonstrating that GTx-101 could deliver bupivacaine systemically via topical application, potentially offering a needle-free alternative for PHN pain management.
- The bioadhesive film-forming polymer platform could have been applicable to other drugs, though this is now moot given the discontinuation.
Bear case
- GTx-101 has been formally discontinued, Grace Therapeutics recorded a $13.5M non-cash impairment of IPR&D for GTx-101 and GTx-102 in Q1 FY2027, confirming the program is dead.
- The company has pivoted entirely to GTx-104, which itself faces regulatory uncertainty after receiving an FDA Complete Response Letter in April 2026.
- GTx-101 never advanced beyond Phase 1 studies, so its clinical and commercial viability was never established.